MLchartDataset catalogue

RET inhibitor SY-5007

Term · Oncology and biomedicine · MLC-T-ONC-016508

An orally bioavailable inhibitor of the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, RET inhibitor SY-5007 selectively binds to and inhibits the activity of RET. This results in an inhibition of cell growth of tumors that exhibit increased RET activity. RET overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and progression of these cancers.

Table 1. Record
IdentifierMLC-T-ONC-016508
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-016508",
  "term": "RET inhibitor SY-5007",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable inhibitor of the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, RET inhibitor SY-5007 selectively binds to and inhibits the activity of RET. This results in an inhibition of cell growth of tumors that exhibit increased RET activity. RET overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and progression of these cancers.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ret-inhibitor-sy-5007/"
}

Record 14,382 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.